OxThera
Manufacturing · Sweden · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Regeringsgatan 111, Stockholm, Stockholm...Phone Number
+46 86600223Website
www.oxthera.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About OxThera
OxThera, founded in 2005 and headquartered in Stockholm, Sweden, is a biopharmaceutical company with products in late-stage clinical development focusing on Primary and Secondary Hyperoxaluria. OxThera’s intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes.Explore more
OxThera Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is OxThera your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if OxThera has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once OxThera has new funding data
Congratulate Masked Content for being promoted to Masked Content at OxThera
Product Launch: Get notified when OxThera launches new products
Earning: See what the market has to say on OxThera recently announced quarterly report
OxThera, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if OxThera had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check out if OxThera is spiking on competitors!
Recommended Actions
Find VP level buyers at OxThera
Find 2 more new buyers
Company Profile Activity
Activity Insights
OxThera is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
OxThera is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about OxThera.
OxThera financials insights
Gather financial insights about OxThera, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Unspecified
$10.6M
2016
Private Equity
$33.9M
OxThera Tech Stack
A closer look at the technologies used by OxThera
OxThera News & Media
New OxThera/Oxabact US patent granted
Stockholm – 25 February 2021. OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces that a new US patent has been granted for its product candidate Oxabact announces that a new US patent has been granted for its product candidate Oxabact, and for a method for the treatment or prevention of an oxalate-related disorder, such as hyperoxaluria. The first formulation of Oxabact was patented and granted back in 1999Plasma oxalate and kidney function are correlated in patients with primary hyperoxaluria with maintained kidney function – Data from three placebo‑controlled studies published
Stockholm – 19 February 2021. OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces the publication of an article in Pediatric Nephrology, on the significant correlation between plasma oxalate and kidney function in three controlled clinical trials with PH patients. Primary hyperoxaluria is a rare autosomal recessive inherited disorder of glyoxylate metabolism that causes an endogenous overproduction of oxalatOxThera Receives Rare Pediatric Disease Designation from U.S. FDA for Oxabact Treatment of Primary Hyperoxaluria
Stockholm – June 26 2020. OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), today announced that the U.S. Food and Drug Administration (“FDA”) has granted a Rare Pediatric Disease Designation for Oxabact OC5. The FDA stated, that based on information provided by OxThera, there is sufficient documentation to demonstrate that nephrocalcinosis, nephrolithiasis, growth failure, and oxalate retinopathy are seriOxThera Announces Completion of Recruitment in Phase 3 ePHex Study With Oxabact® in Patients With Primary Hyperoxaluria
STOCKHOLM, April 6, 2020 /PRNewswire/ -- OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announced today that it has completed enrollment in its Oxabact ePHex phase III study. Oxabact is an investigational...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding OxThera
Sign Up For FreeTo access detailed company insights
OxThera, founded in 2005 and headquartered in Stockholm, Sweden, is a biopharmaceutical company with products in late-stage clinical development focusing on Primary and Secondary Hyperoxaluria. OxThera’s intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes.... Read More
